trametinib,dabrafenib,spartalizumab
novartis
ryan b. corcoran concluding the data on combined pd-1/braf/mek inhibition with spartalizumab, dabrafenib, trametinib in brafv600 crc patients
at 
MD-PhD
Passionate Oncologist
Focus on Molecular Oncology 
Focus on Gastrointestinal Oncology